FIELD: medicine.
SUBSTANCE: there is disclosed application of compound antagonist VEGF representing VEGFR1R2-FcΔCl(a) or Flt1D2. Flk1D3. FcΔCl (a) and antiproliferative agent: paclitaxel, docetaxel, or cisplatin, carboplatin, iproplatin for making a medical product for cancer treatment and/or tumour growth reduction or inhibition in an indigent person (versions), relevant method, pharmaceutical composition and a kit for cancer treatment.
EFFECT: overtotal effect of the disclosed combination (97% tumour suppression) observed without any by-effects.
10 cl, 2 dwg, 1 tbl
Authors
Dates
2009-04-27—Published
2004-07-23—Filed